Global Human Granulocyte Colony-Stimulating Factor Market

Table Of Content

Executive Summary
1. Introduction
Market Introduction
1. Market Definition
2. Scope of the Study
3. Market Structure
Research Methodology
1. Primary Research
2. Research Methodology
3. Assumptions & Exclusions
4. Secondary Data Sources
Market Factor Analysis
1. Value Chain Analysis: Human Granulocyte Colony Stimulating Factor Market
2. Porters Five Forces Analysis
  1. Bargaining Power of Suppliers
  2. Bargaining Power of Buyers
  3. Threat of Substitution
  4. Threat of New Entrants
  5. Competitive Rivalry
Market Dynamics
1. Drivers
2. Restraints
3. Opportunities
Recent Trends Analysis
Impact of COVID-19 on Human Granulocyte Colony Stimulating Factor Market
1. Pre and Post Covid -19 Market Scenario Analysis
2. Market Recovery Timeline and Challenge
3. Measures Taken by Top Players
Regulatory Landscape
Human Granulocyte Colony Stimulating Factor Market, By Type
1. Introduction
  1. Market Size and Forecast, By Type
2. Filgrastim
  1. Market Size and Forecast, By Region
3. Lenograstim
  1. Market Size and Forecast, By Region
4. Pegfilgrastim
  1. Market Size and Forecast, By Region
Human Granulocyte Colony Stimulating Factor Market, By Applications
1. Introduction
  1. Market Size and Forecast, By Applications
2. Chemotherapy-Induced Neutropenia
  1. Market Size and Forecast, By Region
3. Bone Marrow Transplantation
  1. Market Size and Forecast, By Region
4. Severe Chronic Neutropenia
  1. Market Size and Forecast, By Region
5. Others
  1. Market Size and Forecast, By Region
Human Granulocyte Colony Stimulating Factor Market, By End-User
1. Introduction
  1. Market Size and Forecast, By End-User
2. Hospitals
  1. Market Size and Forecast, By Region
3. Clinics
  1. Market Size and Forecast, By Region
4. Others
  1. Market Size and Forecast, By Region
Regional Overview
1. Introduction
  1. Market Size and Forecast
2. North America
  1. Market Size and Forecast
    1. By Type
      1. Filgrastim
      2. Lenograstim
      3. Pegfilgrastim
    2. By Applications
      1. Chemotherapy-Induced Neutropenia
      2. Bone Marrow Transplantation
      3. Severe Chronic Neutropenia
      4. Others
    3. By End-User
      1. Hospitals
      2. Clinics
      3. Others
  2. U.S.
    1. By Type
      1. Filgrastim
      2. Lenograstim
      3. Pegfilgrastim
    2. By Applications
      1. Chemotherapy-Induced Neutropenia
      2. Bone Marrow Transplantation
      3. Severe Chronic Neutropenia
      4. Others
    3. By End-User
      1. Hospitals
      2. Clinics
      3. Others
  3. Canada
3. Europe
  1. Market Size and Forecast
    1. By Type
      1. Filgrastim
      2. Lenograstim
      3. Pegfilgrastim
    2. By Applications
      1. Chemotherapy-Induced Neutropenia
      2. Bone Marrow Transplantation
      3. Severe Chronic Neutropenia
      4. Others
    3. By End-User
      1. Hospitals
      2. Clinics
      3. Others
  2. U.K.
    1. By Type
      1. Filgrastim
      2. Lenograstim
      3. Pegfilgrastim
    2. By Applications
      1. Chemotherapy-Induced Neutropenia
      2. Bone Marrow Transplantation
      3. Severe Chronic Neutropenia
      4. Others
    3. By End-User
      1. Hospitals
      2. Clinics
      3. Others
  3. Germany
  4. France
  5. Spain
  6. Italy
  7. Russia
  8. Nordic
  9. Benelux
  10. Rest of Europe
4. APAC
  1. Market Size and Forecast
    1. By Type
      1. Filgrastim
      2. Lenograstim
      3. Pegfilgrastim
    2. By Applications
      1. Chemotherapy-Induced Neutropenia
      2. Bone Marrow Transplantation
      3. Severe Chronic Neutropenia
      4. Others
    3. By End-User
      1. Hospitals
      2. Clinics
      3. Others
  2. China
    1. By Type
      1. Filgrastim
      2. Lenograstim
      3. Pegfilgrastim
    2. By Applications
      1. Chemotherapy-Induced Neutropenia
      2. Bone Marrow Transplantation
      3. Severe Chronic Neutropenia
      4. Others
    3. By End-User
      1. Hospitals
      2. Clinics
      3. Others
  3. Korea
  4. Japan
  5. India
  6. Australia
  7. Singapore
  8. Taiwan
  9. South East Asia
  10. Rest of Asia-Pacific
5. Middle East and Africa
  1. Market Size and Forecast
    1. By Type
      1. Filgrastim
      2. Lenograstim
      3. Pegfilgrastim
    2. By Applications
      1. Chemotherapy-Induced Neutropenia
      2. Bone Marrow Transplantation
      3. Severe Chronic Neutropenia
      4. Others
    3. By End-User
      1. Hospitals
      2. Clinics
      3. Others
  2. UAE
    1. By Type
      1. Filgrastim
      2. Lenograstim
      3. Pegfilgrastim
    2. By Applications
      1. Chemotherapy-Induced Neutropenia
      2. Bone Marrow Transplantation
      3. Severe Chronic Neutropenia
      4. Others
    3. By End-User
      1. Hospitals
      2. Clinics
      3. Others
  3. Turky
  4. Saudi Arabia
  5. South Africa
  6. Egypt
  7. Nigeria
  8. Rest of MEA
6. LATAM
  1. Market Size and Forecast
    1. By Type
      1. Filgrastim
      2. Lenograstim
      3. Pegfilgrastim
    2. By Applications
      1. Chemotherapy-Induced Neutropenia
      2. Bone Marrow Transplantation
      3. Severe Chronic Neutropenia
      4. Others
    3. By End-User
      1. Hospitals
      2. Clinics
      3. Others
  2. Brazil
    1. By Type
      1. Filgrastim
      2. Lenograstim
      3. Pegfilgrastim
    2. By Applications
      1. Chemotherapy-Induced Neutropenia
      2. Bone Marrow Transplantation
      3. Severe Chronic Neutropenia
      4. Others
    3. By End-User
      1. Hospitals
      2. Clinics
      3. Others
  3. Mexico
  4. Argentina
  5. Chile
  6. Colombia
  7. Rest of LATAM
Competitive Landscape, 2024
1. Introduction
2. Human Granulocyte Colony Stimulating Factor Market Share Analysis, 2024 (%)
  1. Market Share Analysis, 2024
  2. Competition Ranking, 2024
  3. Key Developments & Growth Strategies
    1. Merger & Acquisition
    2. Product Launch
    3. Expansion
  4. Consolidated SWOT Analysis of Key Players
Company Profile
1. Amgen Inc.
  1. Business Overview
  2. Financial Data
  3. Key Product Categories
  4. Recent Developments
2. Novartis International AG
3. Pfizer Inc.
4. Boehringer Ingelheim GmbH
5. Sandoz (Novartis)
6. Mylan N.V.
7. Hikma Pharmaceuticals
8. Teva Pharmaceutical Industries Ltd.
9. Samsung Bioepis
10. Biocon Limited
11. Eli Lilly and Co.
12. Sanofi S.A.
13. AbbVie Inc.
14. Genzyme (Sanofi)
15. Baxter International Inc.

	


A PHP Error was encountered

Severity: Warning
Message:  Undefined array key "list_tbl_fig"
Filename: reports/toc.php
Line Number: 79


	Backtrace:
	
		
	
		
	
		
			
			File: /var/www/html/application/views/frontend/reports/toc.php

			Line: 79

			Function: _error_handler			

		
	
		
	
		
	
		
			
			File: /var/www/html/application/controllers/Web.php

			Line: 215

			Function: view			

		
	
		
	
		
			
			File: /var/www/html/index.php

			Line: 316

			Function: require_once

Check Discount

Get Free Sample

Buy Now

Key Topics Covered

Market Factors (Including Drivers and Restraint)
Market Trends
Market Estimates and Forcasts
Competitive Analysis
Future Market Opportunities

Global Human Granulocyte Colony-Stimulating Factor Market Size, Share & Trends Analysis Report By Type (Filgrastim, Lenograstim, Pegfilgrastim), By Applications (Chemotherapy-Induced Neutropenia, Bone. . . . .

Table Of Content

A PHP Error was encountered